nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
Company profile
Ticker
NRIX
Exchange
Website
CEO
Arthur T. Sands
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nurix, Inc.
SEC CIK
Corporate docs
Subsidiaries
DeCART Therapeutics Inc. ...
IRS number
270838048
NRIX stock data
Latest filings (excl ownership)
8-K
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
S-8
Registration of securities for employees
15 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
11 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
8-K
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
1 Nov 23
10-Q
2023 Q3
Quarterly report
12 Oct 23
8-K
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
12 Oct 23
Latest ownership filings
4
Houte Hans van
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
4
Houte Hans van
15 Feb 24
4
Christine Ring
15 Feb 24
4
Gwenn Hansen
15 Feb 24
4
ARTHUR T SANDS
15 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
Financial summary
Quarter (USD) | Aug 23 | May 23 | Feb 23 | Nov 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 22 | Nov 21 | Nov 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm |
Cash burn (monthly) | 5.55 mm | 362.58 k | 13.34 mm | 13.20 mm | 13.71 mm | 12.17 mm |
Cash used (since last report) | 36.71 mm | 2.40 mm | 88.20 mm | 87.30 mm | 90.67 mm | 80.46 mm |
Cash remaining | 6.49 mm | 40.81 mm | -44.99 mm | -44.10 mm | -47.47 mm | -37.26 mm |
Runway (months of cash) | 1.2 | 112.5 | -3.4 | -3.3 | -3.5 | -3.1 |
Institutional ownership, Q3 2023
94.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 13 |
Closed positions | 11 |
Increased positions | 41 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 350.70 bn |
Total shares | 46.27 mm |
Total puts | 11.20 k |
Total calls | 6.30 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.52 mm | $35.52 bn |
Baker Bros. Advisors | 3.88 mm | $30.51 bn |
Wasatch Advisors | 3.56 mm | $28.02 bn |
Deep Track Capital | 3.00 mm | $23.56 bn |
Redmile | 2.85 mm | $22.39 bn |
Vanguard | 2.71 mm | $21.34 bn |
ARK Investment Management | 2.59 mm | $20.38 bn |
T. Rowe Price | 2.38 mm | $18.69 bn |
Bain Capital Life Sciences Investors | 1.82 mm | $14.33 bn |
STT State Street | 1.77 mm | $13.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Houte Hans van | Common Stock | Sell | Dispose S | No | Yes | 10.0151 | 6,812 | 68.22 k | 68,333 |
13 Feb 24 | Houte Hans van | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Houte Hans van | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Christine Ring | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Christine Ring | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Gwenn Hansen | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Gwenn Hansen | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Arthur T Sands | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 800,000 | 6.98 mm | 800,000 |
News
Analyst Scoreboard: 7 Ratings For Nurix Therapeutics
11 Mar 24
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
11 Mar 24
Nurix Therapeutics Says FDA Lifts Partial Clinical Hold On NX-2127 Phase 1 Trial
11 Mar 24
Morgan Stanley Maintains Equal-Weight on Nurix Therapeutics, Raises Price Target to $10
26 Feb 24
Decoding 4 Analyst Evaluations For Nurix Therapeutics
16 Feb 24
Press releases
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
Nurix Therapeutics to Participate in Upcoming Investor Conferences
6 Mar 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 Feb 24
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
1 Feb 24
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
16 Jan 24